Diligence memo · auto-generated · as of July 3, 2026
Aletheia Therapeutics, Inc.
Aletheia Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Aletheia Therapeutics, Inc. operates in Pharmaceuticals, based in Fort Collins.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aletheia Therapeutics, Inc. has raised $165K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $165K on 2019-03-11.
Most recent recorded round closed around 2019-03-11.
Valuation (modeled)modeled
Provath models Aletheia Therapeutics, Inc. at approximately $7.8M (range $92K–$89M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.58× the median modeled value of Pre-Seed Pharmaceuticals companies in 2019–2021 (46 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 3% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: Elion Oncology, Inc., Cyclone Therapeutics, Inc., Sonnet Biotherapeutics, Inc., Fastball Capital Group, Llc, TamRx, LLC.
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.